ArticleCardiology research2016
Percutaneous Coronary Intervention: Safety of Methotrexate and Its Possible Benefits on Restenosis After Bare-Metal Stent Deployment.
Article in Cardiology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study.European journal of medical research · 2018Trial
- Methotrexate Therapy Promotes Cell Coverage and Stability in in-Stent Neointima.Cardiovascular drugs and therapy · 2021Article
- Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.Rheumatology international · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPercutaneous coronary intervention (PCI) revolutionized treatment of coronary artery disease. Drug-eluting stents are effective and safe but their cost is high, especially for some countries. The primary objective was to evaluate the safety of methotrexate (MTX) in patients who underwent PCI and the secondary goal was to evaluate the possibility that MTX has an impact on restenosis.
methodsThis was a transversal, prospective and descriptive study that recruited 16 patients in whom PCI was planned. MTX was administered to patients at a dose of 5 mg/week for 2 weeks before PCI and 8 weeks after PCI. Bare-metal stent (BMS) deployment was performed according to standard practice. Patients were monitored clinically every 15 days during the first 2 months after the procedure and monthly until 9 months after PCI.
resultsThere were no immediate or late complications associated with PCI. Adverse events and side effects due to MTX occurred in three patients (prevalence 18.7%). These side effects are classified as minor complications. MTX was not discontinued due to these side effects. There were no reported cases of clinical restenosis.
conclusionsMTX was safe in the study population and raised the possibility that a low-cost drug may have positive effects on restenosis after BMS implantation. However, studies with larger sample sizes and other imagine modalities (intravascular ultrasound and/or optical coherence tomography) are required to confirm this hypothesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.